(Q54019566)

23 May 2018

title

Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. (English)

1 reference

23 May 2018

0 references

Mouy R

1

1 reference

23 May 2018

Veber F

2

1 reference

23 May 2018

Blanche S

3

1 reference

23 May 2018

Donadieu J

4

1 reference

23 May 2018

Brauner R

5

1 reference

23 May 2018

Levron JC

6

1 reference

23 May 2018

Griscelli C

7

1 reference

23 May 2018

Fischer A

8

1 reference

23 May 2018

language of work or name

English

0 references

publication date

1 December 1994

1 reference

23 May 2018

The Journal of Pediatrics

published in

1 reference

23 May 2018

volume

125

1 reference

23 May 2018

issue

6 Pt 1

1 reference

23 May 2018

page(s)

998-1003

1 reference

23 May 2018

The electron transport chain of the microbicidal oxidase of phagocytic cells and its involvement in the molecular pathology of chronic granulomatous disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Incidence, severity, and prevention of infections in chronic granulomatous disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Interferon gamma for chronic granulomatous disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Fungal infection in chronic granulomatous disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Itraconazole, a new triazole that is orally active in aspergillosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Treatment of invasive aspergillosis with itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Treatment of invasive aspergillosis with itraconazole in a patient with chronic granulomatous disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Invasive Aspergillus infection in chronic granulomatous disease: treatment with itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Hepatic injury associated with itraconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

In-vitro resistance to imidazole antifungals in Candida albicans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Candida albicans resistance in AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Fluconazole resistance in Candida glabrata

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

The use of ketoconazole as an inhibitor of steroid production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Fluconazole-associated acute adrenal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

High-dose itraconazole in the treatment of severe mycoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Adrenal response to corticotropin during therapy with itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Testosterone treatment in adolescent boys with constitutional delay in growth and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

Itraconazole therapy in aspergillosis: study in 49 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2982023-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(05)82023-2

1 reference

23 May 2018

1 reference

23 May 2018